Clinical Trial Update: Neoadjuvant Doxorubicin, Polyglutamate Paclitaxel, Capecitabine and Metronomic Chemotherapy in Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 neoadjuvant trial for breast cancer using doxorubicin, paclitaxel polyglutamate, capecitabine and metronomic chemotherapy was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Capecitabine (capecitabine)
• Doxorubicin (Adriamycin) (doxorubicin)
• Metronomic chemotherapy (metronomic chemotherapy)
• Paclitaxel polyglutamate (paclitaxel polyglutamate)

Snippet

Sponsor: University of Southern California | Conditions: Breast Cancer | Phase 2 | Status: WITHDRAWN